Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Post by investclubon Dec 06, 2019 8:20am
178 Views
Post# 30428102

Chemo Revenue

Chemo Revenue The Chemotherapy Drug Industry
 
The National Institutes of Health estimated the overall costs of cancer in 2010 at $263.8 billion, of which $102.8 billion was for direct medical costs (total of all health expenditures), $20.9 billion for loss of productivity due to illness and $140.1 billion for cost of lost productivity due to premature death.  By 2017, direct medical costs had risen to an estimated 147.3 billion.  One industry analyst put the size of the global chemotherapy market at $97 billion in 2017.  The analysis group EvaluatePharma estimated total oncology sales in 2018 is $123.8 billion (out of a total prescription medicine market of $864 billion).
 
 
Bullboard Posts